Home / Themes / GLP-1 Short '24: Obesity-Linked MedTech

GLP-1 Short '24: Obesity-Linked MedTech (open on stockthemes)

Last updated

Theme thesis · 4/5 sections · Tickers 3 with notes · 9 pending

Loading chart…
Loading…

Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).

Bull / Bear Details

Widespread adoption of GLP-1 and related obesity treatments may reduce demand for medical devices and procedures used to manage obesity and its complications. S

Thesis

Widespread adoption of GLP-1 and related obesity treatments may reduce demand for medical devices and procedures used to manage obesity and its complications. Sustained weight reduction can improve obstructive sleep apnea and displace some bariatric interventions, creating potential volume pressure for sleep-apnea implants, oral appliances, CPAP equipment, gastric balloons and bariatric surgical consumables. The mechanism is treatment substitution rather than a guaranteed decline in healthcare utilization.

Bull case

  • Broader adoption of GLP-1 therapies for obesity and obstructive sleep apnea encourages patients and clinicians to try pharmacological treatment before implantable stimulation devices, oral appliances or bariatric procedures, reducing new treatment volumes.

  • Sustained weight reduction and improvements in sleep-apnea severity could eventually reduce CPAP initiation, mask replacement and recurring equipment resupply among successfully treated patients, weakening device utilization and recurring consumables demand.

  • Improved efficacy, oral dosing and lower prices for next-generation obesity drugs could expand treatment substitution beyond early adopters, increasing pressure on device-based weight-loss procedures and the surgical instruments used in gastric bypass and sleeve gastrectomy.

Bear case

  • Weight loss does not universally resolve obstructive sleep apnea, and GLP-1 adoption may increase sleep-disorder screening, diagnosis and CPAP initiation, potentially expanding rather than shrinking addressable device demand.

  • Bariatric surgery can provide durable additional weight reduction for patients who do not respond adequately to medication, while high GLP-1 discontinuation rates and weight regain could preserve demand for established surgical and device-based treatments.

  • Medtech companies may diversify into new indications, benefit from improving patient eligibility after weight loss or offset declining obesity-related procedures with other clinical applications, reducing the financial impact of treatment substitution.

Overview

Hiring Trend Watchpoints

High-performing operators are actively adjusting their workforce profiles to defend market share and adapt to GLP-1 adoption curves. In diabetes tech (PODD, TNDM, MMED), watch for aggressive field recruitment directed at primary care physicians (PCPs) and pharmacy channel specialists rather than traditional endocrinology clinics to drive underpenetrated Type 2 automated insulin delivery conversions before metabolic decline slows. In respiratory and home medical equipment (AHCO, RMD), monitor shifts toward digital patient onboarding and automated order intake—such as AdaptHealth hiring ~1,200 workers to staff large capitated IDN contracts while pruning regional administrative headcount via AI. In renal care (FMS, DVA), hiring freezes or net reductions in traditional clinic-level nursing aligned with clinic rationalization (e.g., closing ~100 U.S. clinics) paired with targeted hiring for high-volume hemodiafiltration (5008X HV-HDF) rollouts and value-based care case managers signal defense. Confirmation of thesis execution includes decelerating DME sales recruitment, clinic footprint consolidations, and reduced capital equipment field teams; conversely, sustained hiring surges in traditional CPAP sales and bariatric hardware teams indicate the short thesis is facing resistance.

Forum Watchlist

  • Reddit — r/CPAPHigh

    Patient anecdotes regarding discontinuing CPAP therapy or reducing pressure requirements post-GLP-1 weight loss, contrasted with ongoing mask and supply replenishment sentiment.

  • Reddit — r/ZepboundHigh

    Real-world discussions around the FDA-approved obstructive sleep apnea indication, insurance coverage hurdles, and unassisted resolution of sleep-disordered breathing.

  • Reddit — r/diabetes_t2High

    Reports of insulin de-escalation, elimination of basal/bolus regimens on incretins, and shifts toward or away from automated insulin delivery (AID) patch pumps.

  • Reddit — r/dialysisMedium

    Discussions on delays in dialysis initiation due to kidney disease progression slowing from semaglutide or tirzepatide regimens.

  • Community Forum — Beyond Type 1 / TuDiabetesMedium

    User sentiment comparing hybrid closed-loop pump systems against GLP-1 combination therapies and transitions from MDI injections to tubeless pumps.

Industry Publications

  • MedTech Dive (medtechdive.com) — Covers breaking regulatory clearances, clinical trial milestones, and competitive device displacement across respiratory, renal, and diabetes medtech categories.
  • MassDevice (massdevice.com) — Provides granular intelligence on device manufacturer pipeline execution, quarterly device shipment volume trends, and FDA 510(k)/PMA filings.
  • Medical Device and Diagnostic Industry (MD+DI) (mddionline.com) — Delivers deep sector analysis on medical equipment demand dynamics, payer reimbursement transitions, and device-versus-pharma clinical debates.
  • Sleep Review Magazine (sleepreviewmag.com) — Dedicated journal covering the sleep health clinical workflow, tracking CPAP adherence, hypoglossal nerve stimulation utilization, and oral appliance adoption versus weight-loss drugs.
  • Fierce Medtech (fiercebiotech.com/medtech) — Tracks corporate medtech restructuring, spin-offs (e.g., MiniMed), and emerging competitive technologies fighting pharmaceutical substitution.

Second Order Trends

Several second-order dynamics have reshaped this theme beyond a simple volume contraction story. First, equipment manufacturers are pivoting from denial to co-existence: ResMed has presented registry data from 2.5 million patients arguing that GLP-1 users have 300 to 600 basis points higher CPAP resupply adherence, reframing incretins as a top-of-funnel diagnosis catalyst. Second, diabetes tech pure-plays (Insulet, Tandem, MiniMed) are accelerating transitions away from traditional durable medical equipment (DME) channels into retail pharmacy 'PayGo' models to lower friction and rapidly capture the insulin-intensive Type 2 diabetes population before GLP-1s can delay insulin progression. Third, dialysis operators (Fresenius, DaVita) are managing a demographic timing paradox: while the FLOW trial proved semaglutide reduces major adverse kidney events by 24%, near-term ESRD volumes may see a stabilizing longevity benefit as reduced cardiovascular mortality keeps CKD patients alive longer to eventually reach dialysis. Fourth, invasive device alternatives (Inspire's hypoglossal stimulation and Allurion's gastric balloon) face tightened payer pre-authorization hurdles demanding documented trials of medical weight-loss management before invasive procedural reimbursement.

Search Keywords Brand Product

  • Zepbound
  • Wegovy
  • Mounjaro
  • Ozempic
  • CagriSema
  • Retatrutide
  • Omnipod 5
  • Omnipod 6
  • t:slim X2
  • Tandem Mobi
  • MiniMed 780G
  • MiniMed Flex
  • Simplera
  • Genio implant
  • Inspire hypoglossal stimulation
  • AirSense 11
  • 5008X CAREsystem
  • Allurion balloon
  • FreeStyle Libre 3 Plus
  • Dexcom G7
  • GLP-1 medtech disruption
  • obesity drug device substitution
  • sleep apnea GLP-1
  • OSA CPAP adherence
  • incretin diabetes pump demand
  • ESRD dialysis incidence FLOW trial
  • hypoglossal nerve stimulation GLP-1

Search Keywords Policy Regulatory

  • FDA OSA indication approval
  • CMS ESRD PPS reimbursement
  • Medicare GLP-1 coverage
  • CMS competitive bidding program
  • ADA Standards of Care AID guidelines

Search Keywords Event Phrases

  • ADA Scientific Sessions
  • SLEEP Annual Meeting
  • ASN Kidney Week
  • CHEST Annual Meeting
  • EASD Annual Meeting

Google Trend Product Category Intent

• sleep apnea machine cost • insulin pump without tubes • GLP-1 for sleep apnea • CPAP alternatives • gastric balloon procedure • dialysis treatment options

Google Trend Consumer Intent

• stop using CPAP weight loss • wean off insulin GLP-1 • Zepbound for sleep apnea • best insulin patch pump • can weight loss cure sleep apnea

Google Trend Macro Policy Terms

• Medicare coverage for Zepbound • CMS sleep apnea guidelines • insurance cover GLP-1 for apnea • Medicare insulin pump coverage

Economic Data Watch

1. CDC / NCHS — National Health and Nutrition Examination Survey (NHANES)

Not in registry

Metric/field Obesity Prevalence (Adults, by BMI category)

Cadence irregular

Why it matters Tracks the underlying population affected by obesity, which is the primary target for GLP-1 drugs and the driver of demand for obesity-linked MedTech. A decline in prevalence would signal a long-term headwind for the theme's constituents.

Signal to watch Declining obesity prevalence

Confidence: high

2. CDC / NCHS — National Diabetes Statistics Report

Matched (medium)cand_cdc_nchs_210a4775 · candidate

Metric/field Diagnosed Diabetes Prevalence (Adults, Type 2)

Cadence irregular

Why it matters Monitors the size of the Type 2 diabetes population, which is directly impacted by GLP-1s reducing progression to intensive insulin therapy and related complications. A decline in prevalence would negatively impact diabetes device companies.

Signal to watch Declining Type 2 diabetes prevalence or incidence

Confidence: high

3. USRDS (United States Renal Data System) — Annual Data Report

Not in registry

Metric/field Incidence of End-Stage Renal Disease (ESRD) (per million population)

Cadence annual

Why it matters Tracks the rate of new ESRD cases, which directly impacts the core business of dialysis providers like DaVita and Fresenius Medical Care. GLP-1s have shown a reduction in kidney-disease events, suggesting a long-term decline in ESRD incidence.

Signal to watch Declining ESRD incidence

Confidence: high

4. CMS — Competitive Bidding Program (CBP) Announcements

Not in registry

Metric/field Final Rule and Contract Awards for DMEPOS

Cadence event_driven

Why it matters The CMS CBP directly impacts reimbursement rates and market concentration for Home Medical Equipment (HME) providers, including those in sleep and respiratory health (e.g., AdaptHealth). Changes can materially reshape industry economics.

Signal to watch Aggressive rate cuts or consolidation favoring fewer, larger providers

Confidence: high

5. FRED — Consumer Price Index

Matchedfred · access=api · map_only

Metric/field CPI for Medical Care Services

Cadence monthly

Why it matters Inflation in medical care services impacts the cost structure for healthcare providers and the reimbursement environment. Rising costs without commensurate reimbursement increases can pressure margins for MedTech companies.

Signal to watch Sustained high growth in medical care services CPI

Confidence: low

Free Alt Data Watch

1. ClinicalTrials.gov — Clinical Trial Registry

Matched (medium)cand_clinicaltrials_gov_36d0f449 · candidate

Metric/field Trial Status: 'GLP-1' AND 'sleep apnea' OR 'OSA' (new trials, completion status)

Cadence quarterly

Why it matters Tracks the progression of clinical research into GLP-1s for sleep apnea, which directly threatens the core business of OSA device companies (INSP, SOM.AU, VVOS, RMD, NYXH, FPH.NZ). Positive trial outcomes signal increased substitution risk.

Signal to watch New trial starts, positive results, or completion of trials for GLP-1s in OSA

Confidence: high

2. FDA — Device Approvals (510(k)/PMA)

Not in registry

Metric/field 510(k) or PMA clearances for 'gastric balloon' or 'obesity device' (by manufacturer)

Cadence daily

Why it matters Monitors regulatory approvals for obesity treatment devices, directly competing with GLP-1s (e.g., Allurion). A slowdown in approvals or increased competition in this space would indicate market pressure.

Signal to watch Slowdown in new device approvals or increased competition

Confidence: high

3. Google Trends — Search Interest

Not in registry

Metric/field Search volume for 'Wegovy', 'Ozempic', 'Mounjaro', 'Zepbound' (combined, U.S.)

Cadence daily

Why it matters Indicates general public awareness and interest in key GLP-1 drugs. Sustained or increasing search interest suggests growing adoption and potential for further market penetration, increasing substitution risk for MedTech.

Signal to watch Sustained or increasing search interest

Confidence: medium

4. Reddit — r/diabetes / r/CPAP / r/weightloss

Matched (medium)wingstop_community_posts · access=scrape

Metric/field Post volume and sentiment related to 'GLP-1 impact on devices' or 'GLP-1 side effects' (qualitative analysis)

Cadence weekly

Why it matters Provides qualitative insights into patient experiences, perceived efficacy, side effects, and the impact of GLP-1s on device usage. This can signal shifts in patient preference or adherence that precede official data.

Signal to watch Increasing negative sentiment towards device usage due to GLP-1s, or discussions of GLP-1 side effects impacting adherence

Confidence: medium

5. FDA 510(k) Database — Medical Device Clearances

Matched (medium)cand_fda_1895fbef · candidate

Metric/field 510(k) clearances for 'insulin pump', 'continuous glucose monitor', 'sleep apnea device' (by manufacturer)

Cadence event_driven

Why it matters Tracks new product introductions and competitive activity in the diabetes and sleep apnea device markets. A surge in innovative device approvals could indicate increased competition or attempts to differentiate against GLP-1s.

Signal to watch Increased competitive activity or innovation in device categories directly threatened by GLP-1s

Confidence: high

Paid Alt Data Watch

1. IQVIA — Xponent / National Prescription Audit (NPA)

Matchediqvia_prescription_rx_data · access=file · map_only

Metric/field GLP-1 Prescription Volume (TRx, NRx) (by drug, by indication, by prescriber specialty)

Cadence monthly

Why it matters Provides granular, real-time data on GLP-1 adoption, market share, and prescribing trends. This is the most direct measure of the core theme driver and its impact on the MedTech market.

Signal to watch Accelerating GLP-1 prescription growth, particularly for obesity and T2D, and expansion into new prescriber specialties

Confidence: high

2. YipitData — Healthcare Facility Procurement Data

Matchedyipitdata_hospital_purchasing_medtech_procurement · access=file · map_only

Metric/field Hospital/Surgical Center purchasing volume for 'CPAP machines', 'insulin pumps', 'dialysis equipment' (by manufacturer)

Cadence monthly

Why it matters Offers insights into real-world demand for MedTech devices at the institutional level, providing an early indicator of GLP-1 substitution effects on device utilization and sales.

Signal to watch Declining procurement volumes for obesity-linked MedTech devices

Confidence: high

3. Similarweb — Web Traffic & Engagement

Matchedsimilarweb_website_traffic_engagement · access=file · map_only

Metric/field Website traffic and engagement metrics (unique visitors, time on site) for key GLP-1 drug brand websites (e.g., Wegovy.com, Mounjaro.com) vs. MedTech company websites (e.g., ResMed.com, Insulet.com)

Cadence daily

Why it matters Compares consumer interest and engagement with pharmaceutical solutions versus MedTech devices. A widening gap in favor of GLP-1 drug sites could indicate a shift in patient preference and research.

Signal to watch Increasing web traffic and engagement for GLP-1 drug sites relative to MedTech device sites

Confidence: high

4. Thinknum — Job Postings

Matched (medium)cand_thinknum_5c4f6534 · access=file · candidate

Metric/field Job postings for 'sales', 'marketing', 'R&D' roles (by company: RMD, INSP, TNDM, PODD, FMS, DVA) and for 'GLP-1' related roles (pharma companies)

Cadence weekly/monthly

Why it matters Hiring trends can signal strategic shifts. A slowdown in hiring for MedTech sales/R&D in GLP-1-affected areas, or an acceleration in GLP-1-related roles at pharmaceutical companies, would indicate market shifts.

Signal to watch Decreased hiring in MedTech sales/R&D for affected segments; increased hiring for GLP-1 related roles at pharma companies

Confidence: high

5. Consumer Edge — Transaction Data (Healthcare Facilities)

Not in registry

Metric/field Spend on 'dialysis services' or 'sleep apnea treatment' (by facility type, region)

Cadence monthly

Why it matters Provides insights into actual patient spend and utilization of healthcare services directly related to the theme. A decline in spend on these services could indicate reduced demand due to GLP-1 adoption.

Signal to watch Declining spend on dialysis services or sleep apnea treatments

Confidence: high

Prediction Market Watch

1. When will CMS announce the addition of GLP-1 drugs for obesity to Part D? (Before Jan 20, 2029)

Kalshi · Confidence: high

Matched (medium)pm_kalshi_ddr5_ye2027_above_95 · access=api

Market https://kalshi.com/markets/kxpartdglp1

Why it matters The addition of GLP-1 drugs for obesity to Medicare Part D would significantly expand access and reimbursement for these medications. This would accelerate the adoption of GLP-1s, intensifying the substitution risk for medical device companies in this theme, particularly those focused on obesity treatment (ALUR), sleep apnea (INSP, SOM.AU, AHCO, VVOS, RMD, NYXH, FPH.NZ), and potentially diabetes management (TNDM, MMED, PODD) and dialysis (DVA, FMS) by reducing the progression of obesity-related complications. Increased GLP-1 coverage would be a strong bearish driver for the theme's constituents.

Series key pm_cms_partd_glp1_obesity_coverage

2. Will the FDA approve a cure for Type 1 diabetes before 2033?

Kalshi · Confidence: high

Matched (medium)pm_kalshi_ddr5_ye2027_above_95 · access=api

Market https://kalshi.com/markets/kxfdatype1diabetes

Why it matters While the primary theme driver is GLP-1 impact on obesity-linked conditions, several theme constituents (TNDM, MMED, PODD) have a significant portion of their business tied to Type 1 diabetes management. An FDA approval of a cure for Type 1 diabetes, though a long-term prospect, would fundamentally eliminate or drastically reduce the addressable market for insulin delivery systems and continuous glucose monitors for these companies, representing a profound bearish catalyst for their stock prices.

Series key pm_fda_type1_diabetes_cure

Theme Plain English
This theme captures short exposure to medical technology and healthcare equipment providers exposed to disruption from GLP-1 and multi-incretin therapies. As weight-loss drugs effectively treat obesity and related metabolic conditions, they threaten addressable treatment volumes across sleep apnea devices (CPAP, hypoglossal implants, oral appliances), intensive diabetes management hardware (insulin pumps, automated delivery systems), bariatric devices, and long-term end-stage renal disease dialysis infrastructure.
Key MetricsTable
MetricCadenceWhat It SignalsUpdate Source
GLP-1 prescription ratesMonthlyTracks the adoption rate and market impactGoogle_Sheets
Upcoming Catalysts15 rows
CatalystEstimated TimingEstimated Date StartEstimated Date EndWhy It MattersTicker Or Theme SpecificSource TypesContributing TickersMention CountBase ScoreSource WeightSpecificity WeightMacro BridgeMacro Bridge MultiplierTheme ScoreDate AggregatedManual OverrideBridge Mention CountTheme Base ScoreTheme Importance ScoreSource TypeCatalyst SourceCatalyst IDTranscript Date
Quarterly revenue contribution from AHCO's capitated contract is expected to add incremental percentage points each quarter, culminating in low-double-digit year-over-year growth contribution by Q4 2026.ramping throughout 2026, peaking at low double-digits by Q4 20262026-01-012026-12-31The timing and magnitude of this revenue ramp drive full-year revenue growth and margin expansion; faster-than-expected ramp is bullish, while a slower or smaller ramp is bearish.Tickerearnings_transcriptAHCO10.01.250.921.00.00372026-02-28FalseTheme composer
AHCO plans the rollout of successful AI pilots (order intake AI and conversational AI for PAP self-scheduling) to additional regions.in 20262026-01-012026-12-31Broader deployment could reduce processing times and labor costs and provide margin improvement over time; material upside if deployments accelerate operating leverage beyond current guidance.Tickerearnings_transcriptAHCO10.01.250.921.00.00372026-02-28FalseTheme composer
The CMS competitive bidding program's final rule and subsequent contract awards/implementation for the next round of bidding are expected.upcoming round of competitive bidding (timing uncertain in 2026)2026-01-012026-12-31The final rule and award structure can materially reshape industry reimbursement and market concentration; a rule that consolidates awards to large, efficient providers would be bullish for AdaptHealth, while aggressive rate cuts or broader exclusions could compress margins across Sleep/Respiratory.Themeearnings_transcriptAHCO10.01.250.921.00.00452026-02-28FalseTheme composer
AHCO is pursuing and potentially closing tuck-in acquisitions (equipment/operations) to support West Coast/Hawaii onboarding and broader capitated operations, with associated revolver usage/paydown.through 20262026-02-242026-12-31Small acquisitions can smooth transitions and add local capacity; conversely, additional draws or mis-timed purchases could elevate leverage or integration risk and pressure near-term liquidity and margins.Tickerearnings_transcriptAHCO10.01.250.921.00.00372026-02-28FalseTheme composer
Quarterly revenue contribution from the capitated contract is expected to add incremental percentage points each quarter, culminating in low-double-digit year‑over‑year growth contribution by Q4 2026.ramping throughout 2026, peaking at low double‑digits by Q4 20262026-01-012026-12-31The timing and magnitude of this revenue ramp drive full‑year revenue growth and margin expansion; faster-than-expected ramp is bullish (greater operating leverage), while a slower or smaller ramp is bearish (prolonged margin pressure and higher net leverage).Tickerearnings_transcriptAHCO (ticker)AHCO_8190a9c82026-02-24
Rollout of successful AI pilots (order intake AI and conversational AI for PAP self‑scheduling) to additional regions.in 20262026-01-012026-12-31Broader deployment could reduce processing times and labor costs and provide margin improvement over time; material upside if deployments accelerate operating leverage beyond current guidance, but rollout delays or underperformance would limit anticipated cost savings.Tickerearnings_transcriptAHCO (ticker)AHCO_5c48eab92026-02-24
Effectiveness of diabetes segment recovery initiatives (expanded diabetes sales force and pharmacy/channel investments) to drive a rebound in CGM new starts and continued pump growth.later in 20262026-07-012026-12-31Diabetes performance is a key swing factor for organic growth and valuation; a tangible rebound in new starts would be bullish (restores a previously weak segment and supports guidance), while persistent softness would reinforce downside risk from secular pressures (including GLP‑1 adoption) and hurt revenue and margin outlooks.Tickerearnings_transcriptAHCO (ticker)AHCO_00fc6f4a2026-02-24
Pursuit and potential closing of tuck‑in acquisitions (equipment/operations) to support West Coast/Hawaii onboarding and broader capitated operations, and associated revolver usage/paydown.through 20262026-02-242026-12-31Small acquisitions can smooth transitions and add local capacity (bullish if accretive and enables faster ramp); conversely, additional draws or mis‑timed purchases could elevate leverage or integration risk and pressure near‑term liquidity and margins.Tickerearnings_transcriptAHCO (ticker)AHCO_e7c662522026-02-24
CMS competitive bidding program final rule and subsequent contract awards/implementation for the next round of bidding.upcoming round of competitive bidding (timing uncertain in 2026)2026-01-012026-12-31The final rule and award structure can materially reshape industry reimbursement and market concentration; a rule that consolidates awards to large, efficient providers would be bullish for AdaptHealth (share gains), while aggressive rate cuts or broader exclusions could compress margins across Sleep/Respiratory (bearish).Themeearnings_transcriptAHCO (ticker)AHCO_2dab6ea02026-02-24
Large-scale rollout of the 5008X CAREsystem and high-volume hemodiafiltration (HV-HDF) therapy in U.S. clinics, targeting 20% of the installed base in 2026.in 2026, target of replacing around 20% of the installed base in our own clinics this year2026-01-012026-12-31This strategic initiative is expected to improve patient outcomes, increase operational efficiencies, and strengthen FMS's competitive position, but will incur OpEx headwinds in 2026. Successful execution is crucial for future growth and market share.Tickerearnings_transcriptFMS (ticker)FMS_a8b53d932026-02-24
Phasing out of temporary TDAPA (Transitional Drug Add-on Payment Adjustment) benefits for phosphate binders and antimicrobial catheter solutions.start to phase out in 2026, stronger first half of 2026 before TDAPA benefits begin to phase out in the second half of 20262026-07-012026-12-31These benefits provided a significant positive contribution to earnings in 2025. Their phase-out will create a regulatory headwind of EUR 150M-EUR 200M in 2026, impacting profitability, with uncertainty around the exact erosion of branded pricing and future bundle payments.Tickerearnings_transcriptFMS (ticker)FMS_b10690dc2026-02-24
Continued negative impact from volume-based procurement and other regulatory policies in China on the Care Enablement segment.expected to impact 2026, China remains challenging, and we are assuming moderately negative impact as we address regulatory policy changes and review our portfolio and strategy accordingly2026-01-012026-12-31These policies weighed on revenue and earnings in Q4 2025 and are expected to continue to negatively impact the segment's performance in 2026, with the magnitude dependent on FMS's strategic adjustments.Tickerearnings_transcriptFMS (ticker)FMS_ed8c2ef32026-02-24
Expiry of extended tax subsidies for Affordable Care Act (ACA) contracts.2026 outlook, regulatory headwinds from the expiry of the extended tax subsidies for ACA contracts2026-01-012026-12-31This regulatory headwind is expected to negatively impact earnings development, contributing to the EUR 150M-EUR 200M regulatory impact in 2026, with the full extent of the financial impact still being assessed.Tickerearnings_transcriptFMS (ticker)FMS_9d8ae73c2026-02-24
Recovery of U.S. same-market treatment growth (SMTG) from flat in 2026 towards the historical 2%+ baseline.returning to 2%-plus as mortality normalizes and patient outflows improve, gradually improve over time to get back to that 2% plus2026-01-012028-12-31SMTG is a critical driver of revenue and operating leverage. A sustained recovery would signal normalization of patient mortality and successful strategic initiatives, positively impacting long-term growth and valuation.Tickerearnings_transcriptFMS (ticker)FMS_5e50f0902026-02-24
Realization of an additional EUR 400 million in sustainable savings from the accelerated FME25+ transformation program by the end of 2027, with EUR 250 million incremental savings expected in 2026.for the years '26 and 2027 for a total of EUR 1.2 billion of sustainable savings by the end of 2027, incremental FME25+ savings of EUR 250 million with related onetime cost of EUR 350 million in 20262026-01-012027-12-31This program is a key driver of profitability improvements, aiming for EUR 1.2 billion in total sustainable savings by 2027. Successful execution will significantly boost margins and earnings, offsetting inflationary pressures.Tickerearnings_transcriptFMS (ticker)FMS_23d3f5092026-02-24

News

8 stories tagged to this theme — Narrative Radar and editorial picks.

Loading correlation…

Constituents

  • — AdaptHealth Corp.
  • FMST3
    — Fresenius Medical Care AG & Co. KGaA
  • JNJT3
    — Johnson & Johnson
  • ALURT3
    · no notes yet
  • DVAT3
    · no notes yet
  • FPH.NZT3
    · no notes yet
  • INSPT3
    · no notes yet
  • MDTT3
    · no notes yet
  • NYXHT3
    · no notes yet
  • RMDT3
    · no notes yet
  • SOM.AUT3
    · no notes yet
  • VVOST3
    · no notes yet